| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | - | 344 | 161.947 | 64.627 |
| Total Income - EUR | - | - | - | - | - | - | - | 344 | 162.588 | 64.803 |
| Total Expenses - EUR | - | - | - | - | - | - | - | 239 | 9.979 | 25.086 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | - | 105 | 152.609 | 39.717 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | - | 101 | 151.180 | 33.777 |
| Employees | - | - | - | - | - | - | - | 0 | 1 | 1 |
Check the financial reports for the company - Medipsy R & D S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | - | 0 | 1.205 | 1.755 |
| Current Assets | - | - | - | - | - | - | - | 383 | 151.370 | 33.505 |
| Inventories | - | - | - | - | - | - | - | 0 | 0 | 49 |
| Receivables | - | - | - | - | - | - | - | 0 | 80.584 | 19.968 |
| Cash | - | - | - | - | - | - | - | 383 | 70.786 | 13.487 |
| Shareholders Funds | - | - | - | - | - | - | - | 142 | 151.322 | 34.040 |
| Social Capital | - | - | - | - | - | - | - | 41 | 40 | 40 |
| Debts | - | - | - | - | - | - | - | 242 | 1.253 | 1.220 |
| Income in Advance | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Medipsy R & D S.r.l.